Cellectricon to show Cellaxess technology in Neuroscience 2013 Improved drug compound and delivery identification with the Cellaxess technology Cellectricon, a leading provider of advanced cell-based screening services and systems, will be presenting new data at Neuroscience 2013, november 9-13, NORTH PARK . In some poster presentations, Cellectricon will demonstrate how its technology can be applied successfully for drug discovery, particularly with regards to cytoskeletal disorders and neurodegenerative diseases. The poster session may also reveal an assay for the high-throughput identification of compounds that modulate neuronal excitability. In this real method, attendees will be demonstrated how compound characterization and data-based decision making can be achieved early in a task life-cycle, reducing unnecessary cost and time.The habit outcomes in about 443,000 deaths, or one in five, across the USA annually. Smoking can result in 23 times the chance of cancer for guys, and 13 instances the risk in women, based on the U.S. Centers for Disease Control and Avoidance. ‘House Speaker Nancy Pelosi and her best lieutenants said Thursday they are near corralling the 218 votes they need to move forward with comprehensive legislation that would add a version of the public choice prized by liberals as a fundamental pillar of reform,’ the Washington Post reviews .